Predicting death due to progressive heart failure in patients with mild-to-moderate chronic heart failure  by Kearney, Mark T et al.
Predicting Death Due to Progressive
Heart Failure in Patients With
Mild-to-Moderate Chronic Heart Failure
Mark T. Kearney, DM,* Keith A. A. Fox, FRCP,† Amanda J. Lee, MSC,‡ Robin J. Prescott, PHD,‡
Ajay M. Shah, FRCP,* Philip D. Batin, DM, Wazir Baig, MD,¶ Stephen Lindsay, MD,#
Timothy S. Callahan, PHD,** William E. Shell, MD,†† Dwain L. Eckberg, MD,‡‡
Azfar G. Zaman, MD,§§ Simon Williams, MRCP, James M. M. Neilson, PHD,§ James Nolan, MD¶¶
London, Edinburgh, Pontefract and Wakefield, Doncaster, Bradford, Liverpool, and Stoke-on-Trent,
United Kingdom; Los Angeles, California; and Richmond, Virginia
OBJECTIVES The aim of this study was to explore the value of noninvasive predictors of death/mode of
death in ambulant outpatients with chronic heart failure (HF).
BACKGROUND Mortality in chronic HF remains high, with a significant number of patients dying of
progressive disease. Identification of these patients is important.
METHODS We recruited 553 ambulant outpatients age 63  10 years with symptoms of chronic HF
(New York Heart Association functional class, 2.3  0.5) and objective evidence of left
ventricular dysfunction (ejection fraction 45%, cardiothoracic ratio 0.55, or pulmonary
edema on chest radiograph). After 2,365 patient-years of follow-up, 201 patients had died,
with 76 events due to progressive HF.
RESULTS Independent predictors of all-cause mortality assessed with the Cox proportional hazards
model were as follows: a low standard deviation of all normal-to-normal RR intervals
(SDNN); lower serum sodium and higher creatinine levels; higher cardiothoracic ratio;
nonsustained ventricular tachycardia; higher left ventricular end-systolic diameter; left
ventricular hypertrophy; and increasing age. Independent predictors of death specific to
progressive HF were SDNN, serum sodium and creatinine levels. The hazard ratio of
progressive HF death for a 10% decrease in SDNN was 1.06 (95% confidence interval [CI],
1.01 to 1.12); for a 2 mmol/l decrease in serum sodium, 1.22 (95% CI, 1.08 to 1.38); and for
a 10 mol/l increase in serum creatinine, 1.14 (95% CI, 1.09 to 1.19) (all p  0.01).
CONCLUSIONS In ambulant outpatients with chronic HF, low serum sodium and SDNN and high serum
creatinine identify patients at increased risk of death due to progressive HF. (J Am Coll
Cardiol 2002;40:1801–8) © 2002 by the American College of Cardiology Foundation
Over a half million new cases of chronic heart failure (HF)
are diagnosed each year in the U.S. (1). Despite advances in
understanding of the pathophysiology of chronic HF and
improvements in its therapy, mortality in ambulant outpa-
tients with controlled symptoms currently remains 10%
per year (2,3). A substantial proportion of these deaths are
due to a progressive decline in left ventricular function (2,3).
It is not fully understood why some patients who have a
period of compensated HF after an initial cardiac insult
subsequently enter into an irreversible process of declining
ventricular function. There is compelling evidence, how-
ever, that autonomic and neurohumoral mechanisms play a
critical role in mediating this decline in cardiac function (4).
Agents such as beta-blockers and angiotensin-converting
enzyme (ACE) inhibitors that inhibit specific neurohu-
moral mechanisms prolong life in chronic HF patients, at
least in part, by slowing disease progression (2,5,6). Vari-
ables that reflect the magnitude of neurohumoral dysfunc-
tion, therefore, may help to identify patients with chronic
HF who are at increased risk of entering a decompensated
spiral of declining ventricular function, hemodynamic dete-
rioration, and death due to progressive HF.
Several studies have reported variables that might identify
patients with chronic HF who are at high risk of death, and
their modes of death (7–10). Most of these studies are
retrospective analyses of data from trials of therapeutic
agents, where risk stratification was not the primary objec-
tive (7–9). Additionally, some of these studies were con-
ducted in patients with severe HF (8,9) who may be easier
to identify with bedside assessment, and who have annual
mortality rates 30% (11).
Treatments aimed at preventing death from progressive
HF, as opposed to sudden death, may and currently do
require different strategies. Therefore, identifying patients at
risk of death specifically from progressive HF may help to
tailor further investigation or therapy. The United Kingdom
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Heart failure Evaluation and Assessment of Risk Trial
(UK-HEART) was prospectively designed to assess the
value of noninvasive predictors of mortality and mode of
death (including noninvasive measurements of neurohu-
moral function) in ambulant outpatients with chronic HF.
We now report on five-year follow-up of our study cohort,
with the principal focus of this report on variables that
specifically identify patients at increased risk of death due to
progressive HF. The current study has the longest follow-up
of its type and adds to previous work by evaluating the
long-term prognostic utility of both time- and frequency-
domain measurements of heart rate variability (HRV).
METHODS
Patient enrollment. The UK-HEART was a prospective
study carried out in cardiology outpatient clinics of eight
United Kingdom general hospitals, between December
1993 and April 1995 (12). Consecutive patients of either
gender, age 18 to 85 years, with chronic HF were recruited
on the basis of predefined inclusion and exclusion criteria.
The ethical committee at each institution approved the
protocol, and all patients gave informed consent. Patients
were eligible for the trial if they were ambulant outpatients
with stable clinical signs and symptoms of chronic HF
present for at least three months. We required that symp-
toms be associated with objective evidence of cardiac dys-
function at rest (pulmonary venous congestion, pulmonary
edema, a cardiothoracic ratio 0.55 on at least one chest
radiograph, or a radionuclide or echocardiographic ejection
fraction [EF]45%). To avoid possible confounding effects
on measurements of neurohumoral activity, patients were
excluded if they had a condition associated with impaired
autonomic function (diabetes mellitus or chronic renal
failure unrelated to HF), a history of alcohol abuse, auto-
nomic neuropathy, or a recent (3 months) myocardial
infarction. Patients with documented constrictive or hyper-
trophic cardiomyopathy, sustained nonsinus dysrhythmias,
atrioventricular conduction defects, or a comorbid noncar-
diac disease likely to limit survival were also excluded.
Baseline data collection. At the time of recruitment, a
case record form detailing baseline clinical and demographic
data was completed for each patient. An erect posteroante-
rior chest radiograph was obtained, and the cardiothoracic
ratio was measured. A venous blood sample was taken at rest
for measurements of electrolyte concentrations and assess-
ment of renal and liver function. Two-dimensional and
M-mode echocardiography were performed according to
American Society of Echocardiography recommendations.
Left ventricular cavity dimensions, EF, and fractional short-
ening index were calculated according to standard formulas.
All patients were registered with the United Kingdom
Office of Population Censuses and Surveys, which notified
the Steering Committee of all deaths.
Ambulatory and 12-lead electrocardiography. Twenty-
four hour ambulatory electrocardiogram recordings
(Tracker, Reynolds Medical, UK) were obtained in all
patients during normal, unrestricted out-of-hospital activ-
ity. Recordings were analyzed with a Reynolds Medical
Pathfinder system by independent technical staff blinded to
patient characteristics and outcome data. Nonsustained
ventricular tachycardia was defined as three or more con-
secutive ventricular ectopic beats at a rate 120 beats/min.
Left ventricular hypertrophy was assessed using the
Sokolow-Lyon voltage (sum of the amplitude of the S-wave
on lead V1 and the R-wave on V5 or V6 3.5 mV).
Time-domain analyses of HRV. After initial arrhythmia
analysis and editing, normal-to-normal RR intervals were
identified, and HRV in the time-domain was measured,
according to published guidelines (13). Standard deviation
of all normal-to-normal RR intervals (SDNN) is an index of
total HRV. We have previously demonstrated that SDNN
is a better prognostic marker than other time-domain
measurements and, therefore, confined our prognostic stud-
ies to this index (12).
24-h frequency-domain HRV analyses. Frequency-
domain analyses were made for the first 5 min of each hour
and averaged. Fast Fourier transform power spectra (with
linear interpolation over missing data, resampling at 0.5 Hz,
and Hamming windowing) were integrated over all fre-
quencies total power (TP): 0.0033 to 0.04 Hz very low-
frequency power (VLFP); 0.04 to 0.15 Hz low-frequency
power (LFP); and 0.15 to 0.40 Hz high-frequency power
(HFP) (14,15).
Classification of cause of death. Classification criteria for
the cause of death were defined before the study com-
menced. All deaths reported to the Steering Committee
were evaluated by at least two senior physicians, who
reviewed death certificates, autopsy findings, and hospital
and general practitioners’ records. Where these physicians
did not agree on the cause of death, the case was adjudicated
by the lead investigator. The mode of death was classified as:
1) sudden cardiac, if it occurred within 1 h of a change in
symptoms or during sleep, or while the patient was unob-
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
CI  confidence interval
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eGFR  estimated glomerular filtration rate
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HFP  high-frequency power
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LFP  low-frequency power
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served; 2) progressive HF, if death occurred after a docu-
mented period of symptomatic or hemodynamic deteriora-
tion; 3) other cardiovascular death, if death did not occur
suddenly and was not associated with progression of HF;
and 4) noncardiovascular death.
Statistical analysis. Descriptive group data are given as
mean  SD unless stated otherwise. Estimated glomerular
filtration rate (eGFR) was calculated using the Modification
of Diet in Renal Disease method (16). Natural logarithms
were used for all HRV measurements and cardiothoracic
ratios. The Cox proportional hazards regression model was
used to determine which measurements were related signif-
icantly to mortality during the follow-up period, using a
multivariate forward and backward stepping model. The
Cox model has advantages over other techniques such as
logistic regression. It takes into consideration variable du-
ration of follow-up, censoring of subjects, proportionality of
event occurrence, and time to event. For the prediction of
progressive HF, observations were censored if the patient
died of another cause of death; these patients were included
in the analysis only up to the time that they died. The
causes of death may not be entirely independent, and this
could have an effect on the model. We used receiver
operating characteristic (ROC) analysis to generate
C-statistics. The ROC curves plot the positive fraction, or
sensitivity against the false positive fraction (1-specificity)
by varying the threshold value for the test. The ROC curve
indicates the probability of a true positive result as a
function of the probability of a false positive result for all
possible threshold values. A C-statistic of 0.5 indicates that
the test results are no better than those obtained by chance,
whereas an area of 1.0 indicates a perfectly sensitive and
specific test.
For the prediction of progressive HF, variables entered
into the model were age, gender, the presence or absence of
nonsustained ventricular tachycardia, ventricular hypertro-
phy, left ventricular end-systolic/diastolic diameters, EF,
sodium, potassium, urea, creatinine, and the natural loga-
rithms of the cardiothoracic ratio, SDNN, VLFP, LFP,
HFP, and TP. Where appropriate, Kaplan-Meier cumula-
tive mortality curves were plotted to display trends in
mortality over time and risk ratio. A value of p  0.05 was
taken as statistically significant. The present study has more
events and longer follow-up than our previous report and
most other studies in this area and, thus, higher statistical
power.
RESULTS
Patient characteristics. A total of 553 white patients were
recruited in cardiology outpatient clinics. Patients’ mean age
(and range) was 62.7  9.7 years (18 to 85 years); 76% were
male; 2% were categorized as New York Heart Association
(NYHA) functional class I, 59% as class II, and 39% as class
III. The average NYHA functional class was 2.3  0.5.
Mean serum creatinine was 121  40.8 mol/l (60 to
340 mol/l), and mean sodium was 140  3.2 mmol/l (122
to 148 mmol/l). Of the patients, 76% had ischemic heart
disease as the etiology of their HF, 38% had nonsustained
ventricular tachycardia, and 10% had left ventricular hyper-
trophy.
Most patients (82%) were treated with ACE inhibitors
(mean enalapril dose: 12  0.3 mg/day) and loop diuretics
(99%, mean furosemide dose: 71  69 mg/day). Of the
patients, 19% were taking digoxin at a mean dose of
198.0  7.1 g/day; 14% of patients were taking amioda-
rone (all 200 mg/day); and 7.9% took atenolol at a mean
dose of 43.7  1.6 mg/day. Information on deaths was
recorded up to and including April 2000, allowing five-year
survival status to be determined for all patients. Follow-up
was complete on all patients. Of the cohort recruited, 433
patients had 24-h Holter recordings suitable for HRV
analysis (all had recordings suitable for arrhythmia analysis).
HF severity. The mean left ventricular EF was 42  17%
(6% to 88%), left ventricular end-diastolic diameter was
6.2  1.0 cm (3.2 to 9.4 cm), left ventricular end-systolic
diameter was 5.0  1.2 cm (1.7 to 9.2 cm), and cardiotho-
racic ratio was 0.53 0.07 (0.34 to 0.88). The mean SDNN
was 114  41 ms (17 to 264 ms).
Mortality. An EF of45% was only one entrance criterion
for the present study (see the Methods section). Of the
study population, 64% had EFs 45%, with a total mor-
tality at five years of 42% (with 16% dying of progressive HF
and 15% dying suddenly). A total of 202 patients (36%) had
EFs 45%, with a total mortality at five years of 28% (10%
progressive HF and 8% sudden death). At 5 years (2,365
patient-years), 201 patients had died (mean annual mortal-
ity rate: 7.3%); 67 (33%) of sudden death; 76 (38%) of
progressive HF; 24 (12%) of other cardiac causes; and 34
(17%) of noncardiac causes (Figs. 1A to 1D).
Predictors of all-cause mortality. In multivariate analysis,
eight variables provided independent prognostic informa-
tion that identified patients at increased risk of death from
any cause (Table 1): SDNN, serum sodium and creatinine,
cardiothoracic ratio, nonsustained ventricular tachycardia,
left ventricular end-systolic diameter, the presence of elec-
trocardiographic left ventricular hypertrophy, and increased
age (Table 1). The C-statistic for the all-cause mortality
model is 0.78. When expressing renal function using eGFR
it remained an independent predictor of all-cause mortality,
hazards ratio (HR) 1.32 (95% confidence interval [CI] 1.13
to 1.53) for every 10 ml/min/1.73 m2 decrement in eGFR
(p  0.001).
Predictors of death due to progressive HF. Seventy-six
patients died of progressive HF (Table 1). In multivariate
analysis, independent and specific predictors of progressive
HF death were SDNN and serum sodium and creatinine
(C-statistic: 0.77). When expressing renal function using
eGFR, it remained an independent predictor of death due
to progressive HF, HR 1.83 (95% CI 1.44 to 2.32) for every
10 ml/min/1.73 m2 decrement in eGFR (p  0.001).
These predictors remained important irrespective of EF
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and etiology of chronic HF. The power of serum sodium,
creatinine, and SDNN to predict all-cause mortality or
progressive HF death did not change over the period of
follow-up. Figure 1A shows mode of death in patients with
left ventricular EF 45% and 45%. Figures 1B to 1D
show Kaplan-Meier curves demonstrating the proportion of
patients free of death due to HF, with the population
dichotomized by median values of SDNN, sodium, and
creatinine.
DISCUSSION
Our principal new findings are that measurements of
SDNN and serum sodium and creatinine levels can identify
patients with relatively mild disease who are at high risk of
death specifically due to progressive HF over a five-year
period. In our study, 24-h frequency-domain measurements
of HRV did not provide additional prognostic information
over the simple time-domain measurement SDNN.
HRV and progressive HF. In an earlier report (12) we
showed that SDNN had potential value as an independent
and powerful predictor of mortality due to progressive HF
during approximately one-year follow-up. The current com-
plete five-year report has substantially greater power and
provides novel, clinically important information showing
that among the more complex frequency-domain measure-
ments of HRV added to the current analysis, SDNN
remained the most important marker of risk for death
preceded by progressive HF.
The intriguing observation that SDNN specifically pre-
dicts HF progression probably derives from influences of the
multiple neurohormonal factors that modulate SDNN, an
index of global HRV. In healthy subjects, HRV reflects
Figure 1. (A) Mode of death in patients with ejection fractions (EF) 45% and 45%. (B) Kaplan-Meier survival curve showing proportion of patients
free of death due to progressive heart failure, dichotomized into those with serum sodium levels above (upper line) and below (lower line) the median value
of 140 mmol/l (p  0.001).
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primarily fluctuations of cardiac autonomic activity. Pub-
lished evidence makes the linkage between reduction of
cardiac autonomic activity, captured in our study by the
SDNN measurement, and progression of HF highly plau-
sible. Patients with HF have increased muscle sympathetic
nerve activity (17–19), cardiac norepinephrine spillover (an
index of sympathetic nerve traffic to the heart (19), plasma
catecholamine levels (20), and renin activity (21). Both
sympathetic stimulation (22) and angiotensin (23) reduce
vagally mediated heart rate fluctuations. (Conversely, in-
creased vagal activity reduces myocardial norepinephrine
release.) Reductions of vagally mediated heart rate fluctua-
tions found in patients with HF (24,25) are directly pro-
portional to the level of muscle sympathetic nerve activity
and plasma norepinephrine levels (18).
In addition, there is an intimate relationship between the
sympathetic and renin-angiotensin-aldosterone systems,
such that stimulation of one increases activity in the other
(26). Both norepinephrine (27) and angiotensin II (28) are
powerful promoters of cardiac myocyte hypertrophy and
necrosis, and there is compelling evidence that norepineph-
rine and angiotensin II play pivotal roles in promoting the
progression of clinical HF (4).
Another potential explanation for the ability of SDNN to
predict HF progression is that SDNN is a marker for
changes of myocardial size and geometry, both of which
Figure 1 continued. (C) Kaplan-Meier survival curve showing proportion of patients free of death due to progressive heart failure, dichotomized into those
with serum creatinine levels above (upper line) and below (lower line) the median value of 111mol/l (p 0.02). (D) Kaplan-Meier survival curve showing
proportion of patients free of death due to progressive heart failure, dichotomized into those with standard deviation of all normal-to-normal RR intervals
(SDNN) above (upper line) and below (lower line) the median value of 112 ms (p  0.01).
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may be involved with HF progression (29). A recent study
shows that chronic sinoatrial node stretch reduces HRV
(30), suggesting that SDNN may be a marker for adverse
changes of cardiac morphology, a possibility that warrants
further study. We have previously demonstrated that ACE
inhibitors augment HRV in patients with chronic HF (31).
Of the population we studied, over 80% were already
stabilized on these agents; despite this, SDNN remained an
important predictor of progressive HF death.
Hyponatremia and progressive HF. We have shown, in a
prospective study conducted in the ACE inhibitor era, that
hyponatremia in ambulant outpatients with chronic HF is a
predictor of mortality from pump failure. Lee and Packer
(32), in a trial not specifically designed to identify prognos-
tic factors, reported that patients with severe chronic
HF (with mean EF 17%) and serum sodium levels
137 mmol/l) have a life expectancy half that of patients
with serum sodium levels 137 mmol/l. More recently,
Aaronson et al. (33) showed in a group of patients referred
for cardiac transplantation (with mean EF 20%) that
serum sodium levels are relatively weak predictors of all-
cause mortality, in an already high-risk group of patients.
The mechanism by which hyponatremia predicts HF pro-
gression may involve neurohumoral activity, including par-
ticularly that of the renin-angiotensin-aldosterone system.
Although not demonstrated in the current cohort of pa-
tients, serum sodium correlates closely with plasma renin
activity (5). It is notable that in the study of Lee and Packer
(32), prognosis improved in those patients whose serum
sodium levels increased in response to ACE inhibition.
Serum creatinine and progressive HF. Alterations of fluid
and electrolyte homeostasis are important in the pathophys-
iology of chronic HF (32). Two recent reports highlight the
potential value of impaired renal function as a marker for
increased risk of death in chronic HF. Hillege et al. (34), in
a retrospective analysis of the Second Prospective Random-
ized study of Ibopamine on Mortality and Efficacy study,
showed that creatinine clearance derived from serum creat-
inine, body weight, and age is the most powerful predictor
of all-cause mortality in patients with NYHA functional
class III to IV HF symptoms and EFs 30%. The authors
of that study did not attempt to determine the mode of
death. Consonant with these findings and those of the
present report, Dries et al. (35), in a retrospective analysis of
the Studies Of Left Ventricular Dysfunction (SOLVD)
database, demonstrated that moderate renal insufficiency is
an independent predictor of all-cause mortality and progres-
sive HF. The SOLVD study, however, excluded patients
with creatinine 177 mol/l. The present study shows that
across a wide range (60 to 340 mol/l), each 10 mol/l
increment of creatinine level increases the risk of a progres-
sive HF death by 14%.
While we can only speculate on the pathophysiologic
mechanisms underlying the correlation between renal im-
pairment and left ventricular dysfunction, our data do not
suggest that renal function is simply a marker for impaired
cardiac output. We found no correlation between serum
creatinine levels and any index of cardiac mechanical per-
formance. Thus, it appears that renal dysfunction per se may
contribute to HF progression. The mechanisms underlying
this detrimental cardiorenal interaction warrant further
investigation.
Predictors of progressive HF in ambulant outpatients. The
majority of previous reports discussing risk stratification in
chronic HF have focussed on patients with significant
systolic dysfunction (10). The present study is the first to
assess patients with chronic HF across a wide range of EFs,
as one would expect to see in well-controlled population
studies of chronic HF (36). Our data provide a novel
approach to identify patients with chronic HF with and
without preserved left ventricular systolic function, who are
at increased risk of death preceded by decompensated HF.
Table 1. Predictors of All-Cause Mortality and Predictors Specific to Progressive Heart Failure Death
Cause of Death/Predictor
Survivors at 5
Years
Nonsurvivors at
5 Years
Mann-Whitney U
or 2 Test,
p Value HR (95% CI) p Value
All-cause mortality
SDNN (10%)* 113 (108–118) 91 (84–98)  0.001 1.05 (1.01–1.08) 0.006
Serum creatinine (10 mol/l) 112 (109–115) 136 (129–144)  0.001 1.09 (1.06–1.12)  0.001
Serum sodium (2 mmol//l) 140 (140–140) 139 (138–139)  0.001 1.14 (1.06–1.24)  0.001
Cardiothoracic ratio (10%)* 0.51 (0.51–0.52) 0.55 (0.54–0.56)  0.001 1.23 (1.10–1.37)  0.001
NSVT (present) 51.3 (44.2–58.3) 30.0 (25.1–35.0)  0.001 1.57 (1.20–2.05) 0.001
LVESD (1 cm) 4.85 (4.72–4.98) 5.37 (5.20–5.55)  0.001 1.23 (1.08–1.39) 0.002
LVH (present) 7.9 (5.0–10.8) 15.0 (9.9–20.1) 0.018 1.54 (1.06–2.23) 0.023
Age (10 yr) 61.8 (60.8–62.8) 64.3 (63.0–65.6) 0.003 1.19 (1.02–1.38) 0.027
Progressive heart failure
SDNN (10%)* 109 (105–113) 83 (72–95)  0.001 1.07 (1.02–1.12) 0.012
Serum creatinine (10 mol/l) 117 (113–120) 148 (134–161)  0.001 1.13 (1.08–1.18)  0.001
Serum sodium (2 mmol/l) 140 (140–140) 138 (137–139)  0.001 1.23 (1.09–1.39) 0.001
Values for survivors and non-survivors of the specified cause of death are given as *geometric mean, mean, or percentages with 95% confidence intervals (CI). Hazards ratios (HR)
are for increment in creatinine, cardiothoracic ratio, age, and left ventricular end-systolic diameter (LVESD), and decrement in standard deviation of all normal-to-normal RR
intervals (SDNN) and sodium given in parentheses, or for the presence/absence of left ventricular hypertrophy (LVH) or nonsustained ventricular tachycardia (NSVT). At
five-year follow up there were 201 deaths of all causes of which 76 were progressive heart failure deaths. C-statistic for all-cause mortality model  0.78 and for progressive heart
failure 0.77. Hazards ratios (derived from Cox model) for progressive heart failure death are age-adjusted.
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Study limitations. The UK-HEART study was carried
out before publication of the landmark trials documenting
the benefit of beta-adrenergic blocking drugs and aldoste-
rone antagonists in patients with chronic HF. However, this
in itself may be an advantage of the current dataset, in that
it allows identification of patients on baseline therapy who
warrant more aggressive use of these and possibly other
agents. The present study excluded diabetics and, therefore,
we cannot extrapolate from our data to the diabetic popu-
lation. However, when random blood glucose levels were
incorporated into our statistical analysis, the predictors of
all-cause mortality and mode of death did not change. This
suggests that our results may apply to the diabetic popula-
tion, a possibility that warrants further study.
Determining the cause of death in HF can be difficult.
We dealt with this problem by having two senior physicians
assess the cause of death, according to strict, predefined
criteria. In support of this approach, our data demonstrate
levels of SDNN, sodium, and creatinine that were signifi-
cantly different in patients dying of progressive HF than in
the rest of the cohort. Our population was relatively young
for patients with chronic HF; therefore, the results of this
exploratory analysis should now be assessed and applied in
different HF populations.
Conclusions. We report a five-year follow-up of 553
patients presenting with mild-to-moderate HF, who are
representative of those seen in cardiology and internal
medicine practices. Our study provides insights into the
pathophysiology of progressive HF; simple analysis of 24-h
ambulatory electrocardiograms and measurement of serum
sodium and creatinine levels identify patients at increased
risk for terminal decompensated HF. These results refine
risk stratification of HF patients and may thereby identify
patients who merit aggressive medical treatment or complex
therapeutic regimes.
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